Omi Parikh
0000-0003-4181-7124
Publication & Citation Trends
Publications
82 total
Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + darolutamide + docetaxel) for mHSPC: UK real world data from the RECOMMEND study.
Cited by 0
Semantic Scholar
Adjuvant pembrolizumab in non–clear cell renal cell carcinoma after nephrectomy: An international multicenter study.
Cited by 0
Semantic Scholar
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
Cited by 13
Semantic Scholar
Cabozantinib (C) ± atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Expansion cohorts from the open-label phase 1b COSMIC-021 study.
Cited by 1
Semantic Scholar
Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study.
Cited by 1
Semantic Scholar
Efficacy outcomes 12 months after initiation of darolutamide in non-metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study.
Cited by 0
Semantic Scholar
Transforming kidney cancer treatment through AI-enabled functional precision medicine: The PEAR-TREE2 trial.
Cited by 0
Semantic Scholar
UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results
Cited by 5
Semantic Scholar
Research Topics
Prostate Cancer Treatment and Research
(39)
Renal cell carcinoma treatment
(25)
Radiopharmaceutical Chemistry and Applications
(21)
Bladder and Urothelial Cancer Treatments
(18)
Cancer, Lipids, and Metabolism
(13)
Affiliations
National Health Service
Lancashire Teaching Hospitals NHS Foundation Trust
Cancer Research UK
Yale University
Rosemere Cancer Foundation